Cinacalcet in the management of primary hyperparathyroidism

References

• Melton LJ 3rd. Epidemiology of primary hyperparathyroidism. J. Bone Miner. Res.6(Suppl. 2), S25–S30 (1991).
   PubMedGoogle Scholar
• Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery121(3), 287–294 (1997).
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab.94(2), 351–365 (2009).
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, BilezikianJP. Primary hyperparathyroidism. In: Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism (7th Edition). Rosen CJ (Ed.). Sheridan Press, PA, USA, 302–306 (2008).
   Google Scholar
• Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case–control study. Ann. Surg.223(3), 402–412 (1995).
   Google Scholar
• Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyrodism: proceedings of the Third International Workshop. J. Clin. Endocrinol. Metab.94(2), 373–381 (2009).
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the Type 2 calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther.308(2), 627–635 (2004).
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab.10(2), 66–71 (1999).
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl Acad. Sci. USA95(7), 4040–4045 (1998).
   PubMed Web of Science ®Google Scholar
• Messa P, Alfieri C, Brezzi B. Clinical utilization of cinacalcet in hypercalcemic conditions. Exp. Opin. Drug Metab. Toxicol.7(4), 217–228 (2011).
   Google Scholar
• Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int.67(2), 467–476 (2005).
   PubMed Web of Science ®Google Scholar
• Kawata T, Imanishi Y, Kobayashi K et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur. J. Endocrinol.153(4), 587–594 (2005).
   PubMed Web of Science ®Google Scholar
• Ohashi N, Uematsu T, Nagashima S et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br. J. Clin. Pharmacol.57(6), 726–734 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar GN, Sproul C, Poppe L et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab. Dispos.32(12), 1491–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Padhi D, Salfi M, Harris RZ. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am. J. Ther.14(3), 235–240 (2007).
   PubMedGoogle Scholar
• Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin. Ther.27(11), 1725–1751 (2005).
   PubMed Web of Science ®Google Scholar
• Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin. Pharmacokinet.46(6), 495–501 (2007).
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris RZ, Salfi M, Sullivan JT. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Clin. Pharmacokinet.44(5), 509–516 (2005).
   PubMed Web of Science ®Google Scholar
• Padhi D, Salfi M, Emery M. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents: a randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D9(5), 335–343 (2008).
   PubMedGoogle Scholar
• Padhi D, Harris RZ, Salfi M, Noveck RJ, Sullivan JT. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: Phase 1, open-label, parallel-group, single-dose, single-centre study. Clin. Drug Invest.28(10), 635–643 (2008).
   PubMed Web of Science ®Google Scholar
• Nakashima D, Takama H, Ogasawara Y et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J. Clin. Pharmacol.47(10), 1311–1319 (2007).
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Bone HG 3rd, Marriott TB et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med.337(21), 1506–1510 (1997).
   PubMed Web of Science ®Google Scholar
• Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab.88(12), 5644–5649 (2003).
   PubMed Web of Science ®Google Scholar
• Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab.90(1), 135–141 (2005).
   PubMed Web of Science ®Google Scholar
• Peacock M, Bolognese MA, Borofsky M et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab.94(12), 4860–4867 (2009).
   PubMed Web of Science ®Google Scholar
• Peacock M, Bilezikian JP, Bolognese MA et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab.96(1), E9–E18 (2011).
   PubMed Web of Science ®Google Scholar
• Cetani F, Saponaro F, Banti C et al. Cinacalcet efficacy in patients with moderately severe pimary hyperparathyroidism according to the European Medicine Agency prescription labeling. J. Endocrinol. Invest. doi:10.3275/7970 (2011) (Epub ahead of print).
   Google Scholar
• Dvorak MM, Chen TH, Orwoll B et al. Constitutive activity of the osteoblast Ca2+-sensing receptor promotes loss of cancellous bone. Endocrinology148(7), 3156–3163 (2007).
   PubMedGoogle Scholar
• Vezzoli G, Terranegra A, Arcidiacono T et al. R990G polymorphism of calcium sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int.71(11), 1155–1162 (2007).
   PubMed Web of Science ®Google Scholar
• Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet. Genom.15(1), 29–34 (2005).
   PubMedGoogle Scholar
• Rothe HM, Shapiro WB, Sun WY, Matalon A. Calcium-sensing receptor gene polymorphism Arg990Gly a influences the response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism. Pers. Med.5(2), 109–116 (2008).
   PubMedGoogle Scholar
• Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery140(6), 874–881 (2006).
   PubMed Web of Science ®Google Scholar
• Horjus C, Groot I, Telting D et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J. Pediatr. Endocrinol. Metab.22(8), 741–749 (2009).
   PubMed Web of Science ®Google Scholar
• Akinci B, Comlekci A, Tankurt E. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Exp. Clin. Endocrinol. Diabet.117(3), 142–145 (2009).
   PubMed Web of Science ®Google Scholar
• Fanari Z, Kadikoy H, Haque W, Pacha O, Abdellatif A. Medical management of primary hyperparathyroidism with concomitant multiple myeloma. Inter. Med.49(6), 581–584 (2010).
   PubMed Web of Science ®Google Scholar
• Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am. J. Kidney Dis.48(5), 832–837 (2006).
   PubMedGoogle Scholar
• Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroidcarcinoma. J. Bone Miner. Res.23(12), 1869–1880 (2008).
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Faiman C, Bilezikian JP et al. The effect of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTx. J. Bone Miner. Res.18(Suppl. 2), S171 (Abstract SA 420) (2003).
   Web of Science ®Google Scholar
• Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J. Clin. Endocrinol. Metab.92(10), 3803–3808 (2007).
   PubMed Web of Science ®Google Scholar
• Marcocci C, Chanson P, Shoback D et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J. Clin. Endocrinol. Metab.94(8), 2766–2772 (2009).
   PubMed Web of Science ®Google Scholar
• Falchetti A, Cilotti A, Vaggelli L et al. A patient with MEN1-associate hyperparathyroidism, responsive to cinacalcet. Nat. Clin. Pract. Endocrinol. Metab.4(6), 351–357 (2008).
   PubMedGoogle Scholar
• Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int. J. Endocrinol.2010, 906163 (2010).
   PubMed Web of Science ®Google Scholar
• Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J. Intern. Med.260(2), 177–182 (2006).
   PubMed Web of Science ®Google Scholar
• Reh CM, Hendy GN, Cole DE, Jeandron DD. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J. Clin. Endocrinol. Metab.96(4), E707–E712 (2011).
   Google Scholar
• Lu JY, Yang Y, Gnacadja G, Christopoulos A, Reagan JD. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J. Pharmacol. Exp. Ther.331(3), 775–786 (2009).
   PubMed Web of Science ®Google Scholar
• Khan AA, Bilezikian JP, Kung AW et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.89(7), 3319–3325 (2004).
   PubMed Web of Science ®Google Scholar